A 2 part phase II trial to evaluate ZD1839 [gefitinib; Iressa] and radiotherapy in patients w/locally [with locally] advanced inoperable squamous cell carcinoma of the head and neck

Trial Profile

A 2 part phase II trial to evaluate ZD1839 [gefitinib; Iressa] and radiotherapy in patients w/locally [with locally] advanced inoperable squamous cell carcinoma of the head and neck

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 26 Jan 2011

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jan 2011 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 10 Jan 2007 Status change
    • 13 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top